Different Doses of Naronapride vs. Placebo in Gastroparesis

ClinicalTrials.gov ID: NCT05621811

Public ClinicalTrials.gov record NCT05621811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-blind, Randomised, Placebo-controlled, Dose-finding Phase IIb Trial to Evaluate the Efficacy, Safety, and Tolerability of a 12-week-treatment With Naronapride in Adult Participants With at Least Moderate Idiopathic or Diabetic Gastroparesis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.

Study identification

NCT ID: NCT05621811
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Dr. Falk Pharma GmbH; Industry
Enrollment: 328 participants

Conditions and interventions

Conditions

Gastroparesis

Interventions

Naronapride Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 3, 2023 (Actual)
Primary completion: Aug 12, 2025 (Actual)
Completion: Sep 4, 2025 (Actual)
Last update posted: Oct 7, 2026

2023 – 2025

United States locations

U.S. sites: 23
U.S. states: 12
U.S. cities: 21

Facility	City	State	ZIP	Site status
Dr Falk Investigational Site	Chula Vista	California	91910	—
Dr Falk Investigational Site	Lomita	California	90717	—
Dr Falk Investigational Site	Clearwater	Florida	33756	—
Dr Falk Investigational Site	Doral	Florida	33126	—
Dr Falk Investigational Site	Hollywood	Florida	33021	—
Dr Falk Investigational Site	Maitland	Florida	32751	—
Dr Falk Investigational Site	Miami	Florida	33144	—
Dr Falk Investigational Site	Miami	Florida	33183	—
Dr Falk Investigational Site	Viera	Florida	32940	—
Dr Falk Investigational Site	Kansas City	Kansas	66160	—
Dr Falk Investigational Site	Topeka	Kansas	66606	—
Dr Falk Investigational Site	Crestview Hills	Kentucky	41017	—
Dr Falk Investigational Site	Houma	Louisiana	70363	—
Dr Falk Investigational Site	Marrero	Louisiana	70072	—
Dr Falk Investigational Site	Flint	Michigan	48439	—
Dr Falk Investigational Site	Flint	Michigan	48503	—
Dr Falk Investigational Site	New York	New York	10033	—
Dr Falk Investigational Site	Cleveland	Ohio	44195	—
Dr Falk Investigational Site	Tulsa	Oklahoma	74104	—
Dr Falk Investigational Site	Philadelphia	Pennsylvania	19087	—
Dr Falk Investigational Site	Cordova	Tennessee	38018	—
Dr Falk Investigational Site	Nashville	Tennessee	37211	—
Dr Falk Investigational Site	Harlingen	Texas	78550	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05621811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 7, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05621811 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →